Lung Cancer Trials Ask AI to find trials
Not Yet RecruitingEarly Phase 1NCT07631299
Official study title

Nebulized AER101 in Pre-op NSCLC

Study summary

The primary objective of this pilot study is to determine if AER101 can decrease glycolysis in non-small cell lung cancer (NSCLC). Glycolysis is the process cells use to break down sugar (glucose) into a smaller substance in the fluid part inside the cell. Many lung cancers begin in bronchi, bronchioles and alveoli cells surrounding the airways, which enables nebulization to deposit AER101 on lung tumors. Participants in the study will self-administer AER101 via a hand-held personal nebulizer three times per day (dosing at least 4 hours apart) for 14 days prior to undergoing surgery for lung cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedAER101

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 8, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Not Yet Recruiting

The study is not accepting participants yet.

What kind of study?Early Phase 1

Interventional

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?University of Oklahoma

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Early Phase 1
Sponsor
University of Oklahoma
Interventions being studied
Drug: AER101
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→
Treatment approach
Surgery→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • 18 years or older
  • Agree to sign consent and follow study requirements
  • Recently diagnosed with lung adenocarcinoma or squamous cell carcinoma
  • Primary patients prior to resection
  • Candidate for surgery (patients are qualified for inclusion if surgery or radiation treatment are agreed to)
  • Baseline PET/CT imaging performed at Stephenson Cancer Center available and performed within previous 30 days
Reasons someone may not be able to joinExclusion criteria
  • Recurrent tumor(s)
  • Nodal or metastatic tumor (multiple lung tumors are acceptable)
  • Pregnant patients
  • Patients unable to provide informed consent
  • Prisoners

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • OU Medical Center HospitalOklahoma City, Oklahoma
  • Stephenson Cancer CenterOklahoma City, Oklahoma

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 8, 2026. Always confirm current availability with the study team.

View original record ↗